Selinexor Triplet Highly Active in Relapsed Myeloma
September 16th 2019
The all-oral triplet regimen of 60 mg of weekly selinexor plus lenalidomide and dexamethasone appears to be highly active and well-tolerated in patients with relapsed, refractory multiple myeloma, particularly in patients who did not receive prior lenalidomide, according to results of the multi-arm STOMP study that were presented during the 17th International Myeloma Workshop.